Human Growth Hormone Market Size

Global Human Growth Hormone Market Overview

The Human Growth Hormone Market Size was valued at USD 6.2 Billion in 2023. The Global Human Growth Hormone industry is projected to grow from USD 6.9 Billion in 2024 to USD 13.5 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 11.3% during the forecast period (2024 - 2032).Rising incidence of growth hormone deficiency, and the increasing awareness about endocrine disorders & the effectiveness of growth hormones are fueling the market growth.

Federation Drug Administration (FDA) approved Pediatric somatropin this August 2023, which resulted in market consolidation by stakeholders such as Opko Health and Pfizer Inc. In terms of phase 3 trial data, Somatrogon-ghla is a long-acting injectable proving noninferiority over somatropin in terms of growing height annually. With the same safety profile as somatropin, this endorsement shows Opko Health's commitment to finding innovative therapeutic solutions for children suffering from growth failure.

In August 2023, Federation Drug Administration (FDA) approved Pediatric somatropin this August 2023, which resulted in market consolidation by stakeholders such as Opko Health and Pfizer Inc. In terms of phase 3 trial data, Somatrogon-ghla is a long-acting injectable proving noninferiority over somatropin in terms of growing height annually. With the same safety profile as somatropin, this endorsement shows Opko Health's commitment to finding innovative therapeutic solutions for children suffering from growth failure.

In May 2023, Novo Nordisk declared that the Committee for Medicinal Products for Human Use of the European Medicines Agency had released a favorable statement regarding the weekly use of Sogroya (Somapacitan). The treatment is recommended for children above 3 years who suffer from growth hormone deficiency and adolescents with developmental failure. This positive development highlights the potential of Sogroya as a replacement therapy for endogenous growth hormone in these patient populations.

In April 2023, Ipsen said they would cease the distribution of NutropinAq cartridges, its supplement containing somatropin. The drug was introduced at a time when very few treatment options were available to patients with similar conditions worldwide says Ipsen company officials. However, given new developments in therapeutics, the firm now wants to focus its resources on creating evidence-based improved drugs.

In October 2020, a Phase III clinical trial investigating the effect of growth hormone treatment (Genotropin) on physical and psychosocial health in adults over 30 years with Prader-Willi syndrome was launched by Erasmus Medical Center together with Foundation for Prader-Willi Research and Prader Willi Fonds and Pfizer

Merck KGaA joined forces with Biocorp in October 2022 to design and manufacture the personalized Mallya device for HGH monitoring.

Human Growth Hormone Market Trends

• Rising incidence of growth hormone deficiency boosts market growth

Cushing's syndrome, turner syndrome, down syndrome, Noonan syndrome, Russell-silver syndrome, Prader Willi syndrome, and others are the most common growth hormone disorders across the globe. For instance, in March 2019, according to the National Organization for Rare Disorders, in the US, turner syndrome affects approximately 1 female in 2,000 to 2,500 live female births and estimated that more than 70,000 women and girls have turner syndrome. Moreover, growth hormone deficiency is caused by structural pituitary disease or cranial irradiation and occurs in the context of additional features of hypopituitarism.

Moreover, early diagnosis of endocrine disorders such as Addison’s disease, Cushing’s disease, graves' disease, Hashimoto thyroiditis, hyperthyroidism/hypothyroidism, prolactinoma, and others can substantially improve the chances of successful treatment and prevent severe complications. The government and various international organizations have launched a number of initiatives to raise awareness about early diagnosis. For instance, The International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a US-based nonprofit charitable organization, celebrates International Children’s Growth Awareness Day every year to spread awareness about the early diagnosis and treatment of growth hormone deficiency.

Human Growth Hormone Market Segment Insights

Human Growth Hormone Brand Insights

The Human Growth Hormone market segmentation, based on brand, includes Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, and others. The Norditropin segment held the largest market in 2021 reaching a market value of USD 3.46 billion by 2032. The Skytrofa segment is expected to register the highest CAGR of 11.37% from 2024 to 2032. This is owing to the growing occurrences of growth hormone deficiency diseases, and technological advances, such as recombinant DNA technology, which is anticipated to fuel the growth of the segment. Moreover, Novo Nordisk’s (Denmark) Norditropin HGH injections are conveniently preloaded pen systems that are premixed and prefilled. The market share for this brand is attributed to the brand value, product quality, convenience, and simplicity of administration. Furthermore, Norditropin is convenient to store while traveling as it does not require refrigeration after activation, which increases its preference among patients.

August 2021: Ascendis Pharma A/S (Denmark) has received the US Food and Drug Administration (FDA) approval for SKYTROFA (lonapegsomatropin-tcgd) for treating pediatric patients aged one year and older.

Human Growth Hormone Route of Administration Insights

The Human Growth Hormone market segmentation, based on route of administration, includes subcutaneous, intramuscular, and intravenous. The subcutaneous segment held the largest market in 2021, and the intramuscular segment is expected to register the highest CAGR from 2024 to 2032. The growth of the subcutaneous segment is increasing as it leads to a significant rise in growth rates in patients and a low incidence of antibody development. The majority of GHD drugs are administered through the subcutaneous route of administration. For instance, brands such as Norditropin, Genotropin, Humatrope, Omnitrope, Nutropin, and Saizen are administered subcutaneously. This route of administration injection is reported to be less painful and easier to self-administer. It is also preferred in children and adults, eventually by means of easy-to-use pen-type delivery devices. Moreover, the subcutaneous route is highly preferred for chronic growth hormone therapy.

Human Growth Hormone Application Insights

The growth hormone market data has been segmented by application into pediatric growth hormone deficiency, adult growth hormone deficiency, idiopathic growth hormone deficiency, small for gestational age, turner syndrome, Prader Willi syndrome, and others. The pediatric growth hormone deficiency segment dominated the market in 2021 and small for gestational age is projected to be the faster-growing segment during the forecast period, 2022-2032. Growth hormone deficiency is an endocrine disorder characterized by the low secretion of growth hormones. The market share for the growth hormone deficiency segment is due to the growing prevalence of GHD, increasing penetration of drugs by prominent market players, and increasing awareness about the disease. Moreover, an increasing engagement of major market players in the development of growth hormone products is likely to drive market growth.

June 2021: Novo Nordisk A/S (Denmark) received approval from the US Food and Drug Administration for Wegovy for chronic weight management.

Figure 2: Human Growth Hormone Market, by Application, 2023 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Human Growth Hormone Distribution Channel Insights

Based on distribution channel, the Human Growth Hormone Market has been segmented into hospital pharmacies, retail pharmacies, online pharmacy, and specialty pharmacy. The hospital pharmacies segment dominated the market in 2021, while online pharmacy is projected to be the fastest-growing segment during the forecast period. Moreover, hospital pharmacies are preferred the synthetic or recombinant variants of growth hormone and the ease of availability. In addition, recombinant growth hormone is a prescription medication made available only with a prescription from a physician. Moreover, most hospitals have a policy that patients ought to buy medications prescribed by the practitioners from their premises only.

Human Growth Hormone Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America Human Growth Hormone market accounted for USD 1.76 billion in 2021 and is expected to exhibit an 10.02% CAGR during the study period. North America accounted for the largest market share due to the surging availability of novel drugs, backed by the existence of a high number of renowned firms and supportive reimbursement policies. Moreover, significant government efforts, a well-developed healthcare infrastructure, and a high level of awareness among people is driving the regional market growth during the forecast period.

Further, the major countries studied are: The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: GROWTH HORMONE MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe growth hormone market accounts for the second-largest market share due to the increased burden of growth hormone deficiencies, the rising availability of artificial growth hormones, and extensive R&D activities. The burden of growth hormone deficiency is rising in Europe due to stress, improper sleep and low glucose levels among people. For instance, in 2018, according to the European Medicines Agency, growth hormone deficiency affected around 4.7 in 10,000 people in the European Union (EU). Furthermore, the Germany Growth Hormone Market held the largest market share, and the France Growth Hormone Market was the fastest growing market in the Europe region.

The Asia-Pacific Growth Hormone Market is expected to grow at a CAGR of 11.26% from 2024 to 2032. This is due to factors such as penetration of vendors, and a rise in disposable income. Moreover, a surge in drug approvals and the frequent launch of new products also drive market growth. Moreover, China Growth Hormone Market held the largest market share, and the India Human Human Growth Hormone Market was the fastest growing market in the Asia-Pacific region.

Growth Hormone Key Market Players & Competitive Insights

Major market players are spending a lot of money on R&D to increase their product lines, which will help the growth hormone market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Human Growth Hormone Market industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Novo Nordisk A/S (Denmark) is a Danish pharmaceutical company that discovers, manufactures, and commercializes pharmaceutical products. The company's operating segments are diabetes, hemophilia, growth disorders, obesity, and other biopharmaceuticals. It has a strong clinical pipeline of drugs for type 1 diabetes, type 2 diabetes, obesity, atherosclerosis, hemophilia, and growth disorders. For instance, in September 2020, the FDA has approved Novo Nordisk's long-acting human growth hormone, Sogroya (Somapacitan). It's the first of the company's regulatory filings for the medicine, also submitted in the EU and Japan, to win approval.

Additionally, Pfizer Inc. (US) is a leading research-based biopharmaceutical company applying science and resources to inventive treatments that extend and significantly improve lives. Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For instance, in February 2020, Pfizer Inc. and OPKO's (US) Once-Weekly NGENLA (somatrogon) injection received marketing authorization by European Union for the treatment of pediatric growth hormone deficiency.

Key Companies in the Human Growth Hormone Market includes

• Novo Nordisk A/S (Denmark)


• Pfizer Inc. (US)


• Ascendis Pharma A/S (Denmark)


• EMD Serono (US)


• Ferring B.V. (Switzerland‎)


• Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China)


• Sandoz International GmbH (Germany)


• AnkeBio Co., Ltd (China)


• Ipsen Pharma (France)


• Genentech (US), among others

Human Growth Hormone Market Industry Developments

January 2022: Ascendis Pharma A/S (Denmark) received the European Commission's approval for TransCon hGH for paediatric growth hormone deficiency. TransCon hGH contains somatropin, which is used for paediatric patients diagnosed with growth hormone deficiency.

January 2018: Ferring B.V. (Switzerland‎) recieved approval from US Food Drug and Administration for ZOMACTON injection recombinant human growth hormone (GH) indicated for replacement of GH in adults with GH deficiency.

March 2022: Ipsen Pharma (France) announced the investment in a new state-of-the-art electronic autoinjector for Somatuline Autogel/Somatuline Depot (lanreotide). This product is specifically designed to improve administration and the injection experience for patients.

Human Growth Hormone Market Segmentation

Human Growth Hormone Brand Outlook

• 
  

  Norditropin

  
  


• 
  

  Genotropin

  
  


• 
  

  Humatrope

  
  


• 
  

  Saizen

  
  


• 
  

  Omnitrope

  
  


• 
  

  Skytrofa

  
  


• 
  

  Others

  
  

Human Growth Hormone Route of Administration Outlook

• 
  

  Subcutaneous

  
  


• 
  

  Intramuscular

  
  


• 
  

  Intravenous

  
  

Human Growth Hormone Application Outlook

• 
  

  Pediatric Growth Hormone Deficiency

  
  


• 
  

  Adult Growth Hormone Deficiency

  
  


• 
  

  Idiopathic Growth Hormone Deficiency

  
  


• 
  

  Small for Gestational Age

  
  


• 
  

  Turner Syndrome

  
  


• 
  

  Prader-Willi Syndrome

  
  


• 
  

  Others

  
  

Human Growth Hormone Distribution Channel Outlook

• 
  

  Hospital Pharmacies

  
  


• 
  

  Retail Pharmacies

  
  


• 
  

  Online Pharmacy

  
  


• 
  

  Specialty Pharmacy

  
  

Human Growth Hormone Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America